Denali Therapeutics (DNLI) Stock Forecast & Price Target

Compare

845 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DNLI Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Denali

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DNLI Stock 12 Month Forecast

Average Price Target

$33.10

▲(59.90% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $33.10 with a high forecast of $40.00 and a low forecast of $25.00. The average price target represents a 59.90% change from the last price of $20.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","26":"$26","41":"$41","18.5":"$18.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,18.5,26,33.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21,22.46153846153846,23.923076923076923,25.384615384615383,26.846153846153847,28.307692307692307,29.769230769230766,31.23076923076923,32.69230769230769,34.15384615384615,35.61538461538461,37.07692307692308,38.53846153846153,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21,21.93076923076923,22.861538461538462,23.79230769230769,24.723076923076924,25.653846153846153,26.584615384615386,27.515384615384615,28.446153846153848,29.376923076923077,30.307692307692307,31.23846153846154,32.16923076923077,{"y":33.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21,21.307692307692307,21.615384615384617,21.923076923076923,22.23076923076923,22.53846153846154,22.846153846153847,23.153846153846153,23.46153846153846,23.76923076923077,24.076923076923077,24.384615384615387,24.692307692307693,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.91,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.51,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.74,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$33.10

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mayank Mamtani

B. Riley Securities

$30

Buy

44.93%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Oruka Therapeutics (NASDAQ: ORKA)

Tazeen Ahmad

Bank of America Securities

$29

Buy

40.10%

Upside

Reiterated

03/03/26

Bank of America Securities Remains a Buy on Denali Therapeutics (DNLI)

Andrew Fein

H.C. Wainwright

$32

Buy

54.59%

Upside

Reiterated

03/02/26

Analysts Conflicted on These Healthcare Names: Denali Therapeutics (NASDAQ: DNLI), Eton Pharmaceuticals (NASDAQ: ETON) and Intellia Therapeutics (NASDAQ: NTLA)

Jay Olson

Oppenheimer

$35

Buy

69.08%

Upside

Reiterated

03/02/26

Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Thomas Shrader

BTIG

$32→$36

Buy

73.91%

Upside

Reiterated

03/02/26

Denali Therapeutics (DNLI) Gets a Buy from BTIG

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$40

Buy

93.24%

Upside

Reiterated

02/27/26

Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Myles Minter

William Blair

―

Buy

―

Reiterated

02/27/26

Denali Therapeutics: Underappreciated Hunter Syndrome Launch and 2026 CNS Pipeline Catalysts Support Buy Rating

Paul Matteis

Stifel Nicolaus

$37→$34

Buy

64.25%

Upside

Reiterated

02/27/26

Stifel Nicolaus Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Sandoz Group Ltd (Other OTC: SDZXF)

Rudy Li

Wolfe Research

―

Hold

―

Initiated

02/23/26

Denali Therapeutics initiated with a Peer Perform at Wolfe ResearchDenali Therapeutics initiated with a Peer Perform at Wolfe Research

Sean Laaman

Morgan Stanley

$40

Buy

93.24%

Upside

Reiterated

02/10/26

Morgan Stanley Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)

Laura Chico

Wedbush

$30

Buy

44.93%

Upside

Reiterated

02/06/26

Denali Therapeutics (DNLI) Gets a Buy from Wedbush

Michael Yee

UBS

$25

Buy

20.77%

Upside

Initiated

01/06/26

Denali Therapeutics assumed with a Buy at UBSDenali Therapeutics assumed with a Buy at UBS

Jessica Fye

J.P. Morgan

$26

Buy

25.60%

Upside

Reiterated

11/03/25

Denali Therapeutics (DNLI) Gets a Buy from J.P. Morgan

Joshua Schimmer

Cantor Fitzgerald

―

Buy

―

Reiterated

09/08/25

Denali Therapeutics (DNLI) Receives a Buy from Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mayank Mamtani

B. Riley Securities

$30

Buy

44.93%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Oruka Therapeutics (NASDAQ: ORKA)

Tazeen Ahmad

Bank of America Securities

$29

Buy

40.10%

Upside

Reiterated

03/03/26

Bank of America Securities Remains a Buy on Denali Therapeutics (DNLI)

Andrew Fein

H.C. Wainwright

$32

Buy

54.59%

Upside

Reiterated

03/02/26

Analysts Conflicted on These Healthcare Names: Denali Therapeutics (NASDAQ: DNLI), Eton Pharmaceuticals (NASDAQ: ETON) and Intellia Therapeutics (NASDAQ: NTLA)

Jay Olson

Oppenheimer

$35

Buy

69.08%

Upside

Reiterated

03/02/26

Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Thomas Shrader

BTIG

$32→$36

Buy

73.91%

Upside

Reiterated

03/02/26

Denali Therapeutics (DNLI) Gets a Buy from BTIG

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$40

Buy

93.24%

Upside

Reiterated

02/27/26

Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Myles Minter

William Blair

―

Buy

―

Reiterated

02/27/26

Denali Therapeutics: Underappreciated Hunter Syndrome Launch and 2026 CNS Pipeline Catalysts Support Buy Rating

Paul Matteis

Stifel Nicolaus

$37→$34

Buy

64.25%

Upside

Reiterated

02/27/26

Stifel Nicolaus Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (NASDAQ: DNLI) and Sandoz Group Ltd (Other OTC: SDZXF)

Rudy Li

Wolfe Research

―

Hold

―

Initiated

02/23/26

Denali Therapeutics initiated with a Peer Perform at Wolfe ResearchDenali Therapeutics initiated with a Peer Perform at Wolfe Research

Sean Laaman

Morgan Stanley

$40

Buy

93.24%

Upside

Reiterated

02/10/26

Morgan Stanley Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)

Laura Chico

Wedbush

$30

Buy

44.93%

Upside

Reiterated

02/06/26

Denali Therapeutics (DNLI) Gets a Buy from Wedbush

Michael Yee

UBS

$25

Buy

20.77%

Upside

Initiated

01/06/26

Denali Therapeutics assumed with a Buy at UBSDenali Therapeutics assumed with a Buy at UBS

Jessica Fye

J.P. Morgan

$26

Buy

25.60%

Upside

Reiterated

11/03/25

Denali Therapeutics (DNLI) Gets a Buy from J.P. Morgan

Joshua Schimmer

Cantor Fitzgerald

―

Buy

―

Reiterated

09/08/25

Denali Therapeutics (DNLI) Receives a Buy from Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Denali Therapeutics

3 Months

xxx

Success Rate

8/13 ratings generated profit

Average Return

-4.89%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of -4.89% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

9/13 ratings generated profit

Average Return

+4.03%

a rating ―

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +4.03% per trade.

2 Years

xxx

Success Rate

9/13 ratings generated profit

Average Return

+6.50%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 69.23% of your transactions generating a profit, with an average return of +6.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNLI Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DNLI has received 24 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. DNLI average Analyst price target in the past 3 months is 33.10.

Each month's total comprises the sum of three months' worth of ratings.

DNLI Financial Forecast

DNLI Earnings Forecast

Next quarter’s earnings estimate for DNLI is -$0.65 with a range of -$0.86 to $0.28. The previous quarter’s EPS was -$0.73. DNLI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.

DNLI Sales Forecast

Next quarter’s sales forecast for DNLI is $17.02M with a range of $0.00 to $200.00M. The previous quarter’s sales results were $0.00. DNLI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year DNLI has Performed in-line its overall industry.

DNLI Stock Forecast FAQ

What is DNLI’s average 12-month price target, according to analysts?

Based on analyst ratings, Denali Therapeutics’s 12-month average price target is 33.10.

What is DNLI’s upside potential, based on the analysts’ average price target?

Denali Therapeutics has 59.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DNLI a Buy, Sell or Hold?

Denali Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is Denali Therapeutics’s price target?

The average price target for Denali Therapeutics is 33.10. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $25.00. The average price target represents 59.90% Increase from the current price of $20.7.

What do analysts say about Denali Therapeutics?

Denali Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of DNLI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Denali Therapeutics (DNLI) Stock Forecast & Price Target

DNLI Analyst Ratings

DNLI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Denali Therapeutics

DNLI Analyst Recommendation Trends

DNLI Financial Forecast

DNLI Earnings Forecast

DNLI Sales Forecast

DNLI Stock Forecast FAQ

Detailed List of Analyst Forecasts